{{Rsnum
|rsid=622342
|Gene=SLC22A1
|Chromosome=6
|position=160151834
|Orientation=plus
|GMAF=0.2713
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=SLC22A1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 37.3 | 44.5 | 18.2
| HCB | 72.4 | 23.9 | 3.7
| JPT | 67.9 | 28.6 | 3.6
| YRI | 71.7 | 26.9 | 1.4
| ASW | 62.5 | 35.7 | 1.8
| CHB | 72.4 | 23.9 | 3.7
| CHD | 73.1 | 25.0 | 1.9
| GIH | 0.0 | 0.0 | 0.0
| LWK | 63.8 | 32.4 | 3.8
| MEX | 42.9 | 39.3 | 17.9
| MKK | 75.3 | 21.4 | 3.2
| TSI | 47.5 | 40.4 | 12.1
| HapMapRevision=28
}}{{PMID Auto
|PMID=19381165
|Title=Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus
}}

{{PMID Auto
|PMID=19898263
|Title=Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
}}

{{PharmGKB
|RSID=rs622342
|Name_s=
|Gene_s=SLC22A1
|Feature=
|Evidence=PubMed ID:19898263
|Annotation=Risk or phenotype-associated allele: C/C. Phenotype: This variant modulates the effect of the SLC47A1 rs2289669 polymorphism on the glucose lowering effect of metformin. In users with the SLC22A1 rs622342 CC genotype there was a significant association with change in HbA1c levels and the genetic variation at the SLC47A1 rs2289669 (G to A) polymorphism (-0.68; 95% CI: -1.06 to -0.30; P=0.005). The multiplicative interaction between these two genotypes was statistically significant (-0.52; 95% CI: -0.94 to -0.11; P=0.015). Study size: 98. Study population/ethnicity: Caucasian. metric(s): P=0.005. Type of association: GN.
|Drugs=metformin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110201
}}

{{PMID Auto
|PMID=20680652
|Title=OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users
|OA=1
}}

{{PharmGKB
|RSID=rs622342
|Name_s=
|Gene_s=SLC22A1
|Feature=
|Evidence=PubMed ID:19381165
|Annotation=This intronic variant (rs622342) of the SLC22A1 gene was associated with the glucose-lowering effect of metformin in patients with diabetes mellitus in a study of 102 incident metformin users. For each minor C allele of this variant, the reduction in HbA1c levels was 0.28% less (95% CI 0.09-0.47, P=0.005).
|Drugs=metformin
|Drug Classes=
|Diseases=Diabetes Mellitus
|Curation Level=Curated
|PharmGKB Accession ID=PA164742818
}}
{{PMID Auto
|PMID=21241070
|Title=Clinical pharmacokinetics of metformin
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs622342
|overall_frequency_n=89
|overall_frequency_d=126
|overall_frequency=0.706349
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=75
|n_articles=2
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22882994
|Title=Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
}}

{{PMID Auto
|PMID=23612856
|Title=Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}